Dabrafenib Recruiting Phase 2 Trials for Tumor Skin / Melanoma Stage IIIb-IVM1a / BRAF Gene Mutation / Metastasis Skin / Melanoma (Skin) / Melanoma Stage IIIb-IVM1B Treatment

Indications	Status	Purpose	Phase
DBCOND0115178 (Tumor Skin) DBCOND0120675 (Melanoma Stage IIIb-IVM1a) DBCOND0061045 (BRAF Gene Mutation) DBCOND0120233 (Metastasis Skin) DBCOND0028446 (Melanoma (Skin)) DBCOND0120232 (Melanoma Stage IIIb-IVM1B)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT03972046	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	Talimogene laherparepvec (DB13896) Trametinib (DB08911) Dabrafenib (DB08912)